10 March 2021 in Research and Practical Medicine Journal
The analysis of the current evidence base concerning the use of oral nutritional supplements (ONS) in gastric cancer (GC) has been made. Databases of scientific information eLIBRARY.ru and PubMed were used. Emphasis is placed on randomized clinical trials and meta‑analyses. The application of ONS is suggested for all patients who undergo to surgical treatment for GC. Its use allows increasing protein and energy consumption, improving the quality of life, some parameters of nutritional status and immunity (albumin, blood lymphocytes etc.). In patients with severe malnutrition (SM) ONS can significantly reduce the incidence of clinically important postoperative complications. The use of this type of medical nutrition in the first 5 days after surgery is safe and does not increase the rate of anastomotic leak. After gastrectomy (GE) its administration reduces the time of recovery of bowel motor function and the duration of hospitalization. After distal GE delay of gastric emptying may occur. In patients with SM, early start of enteral nutrition should be considered. After discharge from the hospital ONS can decelerate the progression of malnutrition, improve the tolerance of adjuvant chemotherapy and improve the quality of life. These effects are most clear after GE and in patients with a high risk of malnutrition (NRS‑2002 ≥ 3). There are no evident advantages of any particular type of ONS in patients with GC. When choosing a specific product, preference should be given to formulas with optimal nitrogen: non‑protein kilocalories ratio, osmolarity closest to physiological and individually selected organoleptic properties. It is recommended that the patient consume at least 200–250 ml of the mixture per day, and in the early postoperative period focus have to be made not on the target volume, but on signs of tolerability.
31 July 2025 in Annals of Critical Care
СЕС.м. Ефремов С.м. Ефремов
С.м. Ефремов С.м. Ефремов
ИЛИлья Наумович Лейдерман
+49
INTRODUCTION: Nutritional support is an integral part of the treatment process in the intensive care unit (ICU). Patients in critical care receive some methods of enteral or parenteral nutrition based on often conflicting guidelines and controversial strategies. OBJECTIVE: To identify key trends in the use of metabolic control and nutritional support technologies in ICUs of different profiles. MATERIALS AND METHODS: The project of this screening study was developed by members of the FAR RF Committee on Nutritional Support and Metabolic Control. The design trial was simple random sampling. The study included 569 ICU patients. Results. The mean age of the patients was 59.22 ± 17.93 years. APACHE II scale — 1.3 ± 3.9 points, according to SOFA scale — 3.7 ± 1.5 points. 56 % of patients underwent surgical interventions, 45 % were on mechanical ventilation, 28-day mortality — 24 %. In 25 % of oncological patients the total protein was below 50 g\l. Serum albumin level was statistically significantly lower (p = 0,013) in the group of patients with acute cerebral insufficiency (ACI) in comparison with oncosurgical patients. In 25 % of multidisciplinary ICU patients albumin concentration was below 25 g/l. Energy requirement was determined empiricaly in 44 % of oncologic patients, in 50 % of patients with ACI the method of c equations was used, and indirect calorimetry was used in all groups in no more than 1 % of cases. Protein requirements were empirically determined in 20 % of cases in all groups. 35 % of physicians estimated the protein requirement based on the value of 1.2–1.5 g/kg/day. Enteral tube feeding was more frequently used by 70 % of ACI patients and 29 % in the oncology group. In contrast, 29 % of oncologic patients received parenteral nutrition. Only 5 % of patients with ACI required parenteral nutrition. CONCLUSIONS: The majority of ICU patients are characterized by such manifestations of protein-energy deficiency as hypoproteinemia, hypoalbuminemia, hypotransferrinemia. Enteral tube feeding is the prevailing method of nutritional support in ICU. The main problem identified in the course of screening should be considered the very rare use of metabolic monitoring technologies and the lack of a personalized approach to the selection of the nutritional support program.
10 December 2023 in Journal of Modern Oncology
Aim. Computed tomographic preoperative assessment of sarcopenia in patients with gastric cancer as a part of combined treatment and the study of the relationship between sarcopenia and postoperative complications. Materials and methods. We analyzed retrospectively the data of 65 patients with morphologically verified diagnosis of stage IIA–IIIC gastric cancer. All patients at stage I of the combined treatment received neoadjuvant chemotherapy (NCT) according to the FLOT regimen, and then a gastrectomy with D2 lymph node dissection was performed. Computed tomography (CT) scans were performed before NCT initiation and 3.5 to 5 weeks after NCT completion for preoperative staging and assessment of tumor response. Using the obtained CT data, CT sarcometry was performed by calculating the cross-sectional area of skeletal muscles at the LIII vertebra level and the “skeletal-muscular index”. Postoperative complications were assessed using the Clavien–Dindo classification. Non-parametric comparison methods were used to assess the significance of differences between groups and subgroups (Wilcoxon T-test, Pearson χ2 test). Differences were considered statistically significant at p0.05. Results. We analyzed the incidence of sarcopenia in the examined patients before the NCT and immediately before the surgery. Sarcopenia was noted in 41 (63.1%) of 65 patients before NCT and in 50 (76.9%) patients after NCT, which indicates its high prevalence in patients with stomach cancer and the adverse effect of NCT on the muscular status of patients (76.9% versus 63.1%). Postoperative complications were diagnosed in 12 of 65 patients (18.5%). The rate of postoperative complications in patients with and without sarcopenia was not statistically significantly different (p=0.392); however, complications of Clavien–Dindo grade ≥IIIb occurred only in patients with sarcopenia (p0.001). Conclusion. According to our data, NCT in gastric cancer aggravates preoperative nutritional disorders. CT, as a standard method of staging and assessing the tumor response to NCT for gastric cancer, provides a tool to assess the state of muscle mass in patients before and after NCT. Preoperative sarcopenia is a risk factor for severe postoperative complications in patients with gastric cancer after gastrectomy.
7 January 2020 in Siberian journal of oncology
ПЕРИОПЕРАЦИОННАЯ НУТРИТИВНАЯ ПОДДЕРЖКА ПРИ РАКЕ ЖЕЛУДКА: СОВРЕМЕННОЕ СОСТОЯНИЕ ВОПРОСА
22 October 2025 in Russian Journal of Anesthesiology and Reanimatology
The problem of postoperative nausea/vomiting (PONV) remains actual, especially for high risk patients. Objective. To analyze the effect of premedication with trimeperidine and taphalgin on the risk of PONV after thyroid surgery in young non-smoking females. Material and methods. There were 70 non-smoking female patients younger 50 years after thyroid surgery: group 1 (n=35) — premedication with trimeperidine, group 2 (n=35) — premedication with selective agonist of μ1 opioid receptors (taphalgin). The incidence and intensity of PONV within a day after surgery were assessed. Results. The absolute risk of postoperative nausea was 71.4% (95% CI 55.0—85.4%) and 31.4% (95% CI 16.9—48.2%) (p=0.0008), vomiting — 48.6% (95% CI 31.8—55.5%) and 22.9% (95% CI 10.3—38.6%) (p=0.023), respectively. The absolute risk reduction for nausea and vomiting was 40% (95% CI 16.6—57.8%) and 25.7% (95% CI 3.3—0.95%), respectively. The NNT score was 2.5 (95% CI 1.7—6.0) for nausea and 3.9 (95% CI 2.2—30.6) for vomiting. NRS scores of nausea were similar in both groups: 4 (3—6) and 4 (2—4) points, respectively (p=0.36). Course of anesthesia and early postoperative period, including the incidence of other complications, did not differ between groups. Conclusion. Premedication with taphalgin instead of trimeperidine is advisable in patients with high risk of PONV.
22 October 2026 in Messenger of ANESTHESIOLOGY AND RESUSCITATION
Introduction. Postoperative nausea and vomiting (PONV) remain a major issue, mainly for particular, high-risk patient populations undergoing surgical intervention for thyroid carcinoma. The objective was to evaluate PONV risk factors for non-smoking women under the age of 50 being operated on for thyroid carcinoma by total thyroidectomy. Materials and methods. Seventy non-smoking female patients, aged 18–50 years, undergoing surgical operation for thyroid carcinoma by total thyroidectomy were examined. The female patients were divided into groups based on PONV occurrence, with a subsequent prognostic significance evaluation of various risk factors accompanying this condition. On every occasion, integrated precautions, including dexamethasone and ondansetron, were carried out.
Results
.
The findings identified an examined case frequency of 51.4% for nausea and 35.7% for vomiting. The impact of age, ASA score, BMI category, surgery duration, and intraoperative fentanyl dosage on the determined frequency was not detected. The premedication type demonstrated statistically considerable prognostic value at or above the average. The use of taphalgine versus trimeperidine resulted in the odds of nausea reduction by a factor of 5.45 (OR 0.183; 95% CI: 0.066–0.510; AUC 0.700; 95% CI: 0.578–0.822; p < 0.001) and vomiting by 3.19 (OR 0.314; 95% CI: 0.112–0.879; AUC 0.640; 95% CI: 0.501–0.779; p = 0.026).
Conclusions
.
The premedication type may affect the PONV incidence among non-smoking females under the age of 50 being operated on for thyroid carcinoma by total thyroidectomy.